[Skip to content]

Print this page

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 361-380


NICE TAs 341-360






DHFT Formulary link


East Midlands Cancer Network link (cancer drugs only)

TA 341

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

2.8 Anticoagulants

TA 342

vedolizumab for treating moderately to severely active ulcerative colitis               

1.5.3 Drugs affecting the immune response               

TA 343

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia


EMCN guidelines            
TA 344

Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia


EMCN guidelines
TA 345

Naloxegol for treating opioid induced constipation

1.6 Laxatives 


TA 346

Aflibercept for treating diabetic macular oedema

11.8 Miscellaneous ophthalmic preparations

TA 347

Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer


EMCN guidelines 
TA 348

Everolimus for preventing organ rejection in liver transplantation               

Not recommended by NICE

TA 349

Dexamethasone intravitreal implant for treating diabetic macular oedema

11.4 Corticosteroids and other anti-inflammatory preparations

TA 350

Secukinumab for treating moderate to severe plaque psoriasis

13.5.3 Drugs affecting the immune response          

TA 351

Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)

NICE Appraisal terminated               

TA 352 

Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy

1.5 Treatment of chronic diarrhoeas

TA 353      

Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

  Terminated appraisal 
TA 354

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism

2.8 Anticoagulants

TA 355      

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

2.8 Anticoagulants


TA 356 

Ruxolitinib for treating polycythaemia vera (terminated appraisal)

 Appraisal terminated

TA 357

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab


EMCN guidelines
TA 358

Tolvaptan for treating autosomal dominant polycystic kidney disease

6.5 Hypothalamic and pituitary hormones and anti-oestrogens

TA 359

Idelalisib for treating chronic lymphocytic leukaemia

TA 360

Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer


Not recommended